Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy

2 novembre 2026 mis à jour par: Wake Forest University Health Sciences

A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting

The purpose of this research study is to see if a wearable temperature monitoring patch can detect cytokine release syndrome earlier than traditional oral temperature monitoring.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

This randomized pilot study is designed to evaluate the efficacy of a continuous temperature-monitoring wearable patch in patients receiving CAR-T therapy in the outpatient setting, comparing its performance to standard institutional monitoring protocols.

Type d'étude

Interventionnel

Inscription (Estimé)

105

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • North Carolina
      • Charlotte, North Carolina, États-Unis, 28204
      • Winston-Salem, North Carolina, États-Unis, 27103
        • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Patients:

  1. Ability to understand and willingness to sign an IRB-approved informed consent
  2. Age ≥ 18 years at the time of consent
  3. Scheduled to undergo CAR-T therapy in the outpatient setting at AHWFBCCC
  4. Ability to read and understand the English and/or Spanish language
  5. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
  6. Access to a mobile device for the duration of the trial

Provider/Staff:

Provider/staff participants must meet all of the following inclusion criteria to participate in the study:

  1. Verbally agree to participate
  2. Hospital at Home outpatient provider/advanced practice provider/nurse of at least one patient participant enrolled on Arm A who completed 14 days of temperature monitoring

Exclusion Criteria:

Patients:

  1. Planned prophylactic tocilizumab for mitigation of CRS as documented in the clinical trials pathway submission
  2. History of silicone allergy
  3. History of Medical Adhesive-Related Skin Injury (MARSI)
  4. Known skin condition that might preclude safe application of the patch, in the opinion of the enrolling investigator

Provider/Staff:

None

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: Arm A: TempShield Continuous Temperature Monitoring plus SOC Temperature Monitoring

Standard of care oral temperature monitoring plus TempShield continuous temperature monitoring patch

Patient participants will receive instruction from a research designee regarding use of the TempShield patch and smartphone application for continuous at-home temperature monitoring. Patient participants will complete onboarding of the application on their smartphone with assistance from the research designee, if necessary. Patient participants should place the patch immediately after completion of CAR-T infusion in the outpatient setting, with assistance from the research designee.

Autre: Arm B: SOC Temperature Monitoring

Standard of care oral temperature monitoring

Standard of care oral temperature monitoring

Aucune intervention: Arm C: Provider/Staff

Providers/staff are Hospital at Home personnel who support patients undergoing outpatient CAR-T therapy and who have monitored at least one participant enrolled on Arm A of the study.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Time to first recorded temperature elevation indicative of Cytokine Release Syndrome (CRS)
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from the initiation of CAR-T infusion to the first occurrence of a recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Participants who do not experience this defined temperature elevation within the 14 days will be censored at the time of their last recorded temperature reading during this window. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of temperature elevation indicative of Cytokine Release Syndrome (CRS)
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience at least one recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of high-grade (grade 2 or higher) Cytokine Release Syndrome (CRS)
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience grade 2 or higher CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to resolution of Cytokine Release Syndrome (CRS) from temper elevation indicative of CRS (temperature ≥ 100.4 °F)
Délai: From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.

Time (in hours) from the from onset of fever indicative of CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period to resolution (i.e., when the participant no longer meets the CRS diagnostic criteria). If a participant experiences multiple episodes of CRS during the 14-day post-CAR-T observation period, the duration can be calculated per episode and cumulatively. This will be calculated for participants experiencing CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
Time to intervention after fever detection (temperature ≥ 100.4 °F)
Délai: From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.

Time (in hours) from documented temperature elevation of ≥ 100.4° F to clinician intervention (e.g., supportive care, medication followed by observation, etc.). This will be calculated for participants experiencing CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
Incidence of admission to the Intensive Care Unit (ICU) due to temperature elevation indicative of CRS
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants admitted to the ICU due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to discharge after admission to the Intensive Care Unit (ICU)
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from ICU admission to ICU discharge. If a participant has multiple ICU admissions during the 14-day post-CAR-T observation period, the duration will be calculated cumulatively. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Length of hospital stay
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of inpatient nights from hospital admission to hospital discharge due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. If a participant has multiple hospital admissions due to CRS during the 14-day post-CAR-T observation period, the duration reported will be cumulative across all stays. This endpoint will be calculated for participants admitted to this hospital during the 14-day post-CAR-T observation period due to temperature elevation indicative of CRS. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants experiencing ICANS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Largest change in body temperature from baseline recorded during the 14-day post-CAR-T observation period
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The maximum numerical difference in body temperature recorded from baseline during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of hours during the 14-day post CAR-T observation period when patch was worn
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The proportion of hours during the 14-day post-CAR-T observation period in which at least one valid human body temperature reading (86 °F to 108 °F) was recorded by the wearable patch, defined as Total adherence = (Number of hours with at least one valid temperature reading)/(24*14 hours). This will be calculated for participants randomized to wear the remote temperature monitoring device.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of paired temperature readings from the temperature patch and an oral thermometer within one degree Fahrenheit in a five-minute window during the 14-day post-CAR-T observation period
Délai: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The number 5-minute intervals in the 14-day post-CAR-T observation period (from the first patch reading indicating a temperature from 86 °F to 108 °F), when concordance between the temperature patch and an oral thermometer within one degree Fahrenheit was observed.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Patient satisfaction with CAR-T temperature monitoring methods
Délai: The Day 14 post-infusion (+28 days) study calendar visit.

Patient satisfaction as assessed by the study survey, evaluating satisfaction on a Likert scale where higher scores indicate a higher level of patient satisfaction with the assigned monitoring method (standard of care vs. wearable patch).

The Day 14 post-infusion (+28 days) study calendar visit.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Cindy Varga, MD, Wake Forest University Health Sciences

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 août 2028

Achèvement de l'étude (Estimé)

2 janvier 2029

Dates d'inscription aux études

Première soumission

26 octobre 2026

Première soumission répondant aux critères de contrôle qualité

26 octobre 2026

Première publication (Réel)

2 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IRB00158734
  • ONC-MM-2501 (Autre identifiant: Atrium Health Wake Forest Baptist Comprehensive Cancer Center)

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .